. . . . . . . "[In the pivotal coBRIM trial, previously untreated patients with BRAF (V600) mutation-positive unresectable, stage IIIC or stage IV melanoma received cobimetinib 60�mg once daily for the first 21�days of each 28-day cycle plus vemurafenib 960�mg twice daily or vemurafenib alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:03+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .